Introduction
Newcastle disease virus (NDV) is used to treat human cancer either in the form of free virus 1 or in the form of virus-infected tumor cell vaccine. 2 Three cellular mechanisms have been proposed for its anti-neoplastic activities: (i) oncolysis: 3 oncolytic strains may simply kill tumor cells directly. (ii) Provision of danger signals: 4, 5 replication of NDV occurs in the tumor cells' cytoplasm. It is associated with the production of single-and doublestranded viral RNA. NDV infection of tumor cells thus introduces danger signals 6 that can be recognized by RIG-I 7 and PKR 8 in the cytoplasm and by Toll-like receptors 9 in endosomes. (iii) Immune cell activation: application of NDV may stimulate the host to produce cytokines such as interferons (IFNs) or tumor necrosis factor (TNF), which in turn leads to the activation of natural killer (NK) cells, monocytes, macrophages and sensitized T cells.
In our laboratory, we have established a tumor vaccine, which consists of irradiated autologous tumor cells, infected with the non-lytic NDV strain Ulster.
Already in 1986, we first reported on successful postoperative active-specific immunotherapy (ASI) with virus modified-but not with unmodified-murine ESb lymphoma cells, which caused protection from metastases in about 50% of syngenic mice. 10 Protective antitumor immunity in the ESb lymphoma model was highly specific for the autologous tumor line. 11 On the basis of these preclinical observations, we subsequently established a similar autologous NDV virus-modified tumor vaccine (ATV-NDV) for human application. 2, 12 Recently, we reported results from two non-randomized phase II studies, which aimed at feasibility, safety and clinical benefit. In both studies (glioblastoma multiforme (GBM) 13 and head and neck carcinoma (HNSCC) 14 ), the establishment of primary tumor cell cultures was feasible and successful in about 80-90%. All tumor cells tested could be successfully infected by NDV and showed cell surface expression of MHC I and viral HN molecules. Clinical benefits in GBM included one complete remission and prolongation of median overall-survival (100 weeks versus 49 weeks in controls 13 ). Clinical benefits in the HNSCC study included improvement of the 5-year survival rate in stage III and IV (61 versus 38%). 14 In recent years, reverse genetics technology enabled to generate recombinant strains from non-segmented negative strand RNA viruses. Such techniques allowed recovering recombinant NDV entirely from cloned cDNA of the non-lytic strain La Sota. 15 The aim of this study was to optimize a tumor vaccine by increasing the induced anti-tumor immunity. Recombinant (rec) NDV strains with an inserted therapeutic gene encoding either human or murine GM-CSF were thus produced. We will demonstrate a significant augmentation of anti-tumor activity upon stimulation of human peripheral blood mononuclear cells (PBMCs) from healthy donors with tumor vaccine infected with rec(GM-CSF) in comparison to a vaccine infected with recombinant NDV without a foreign gene (rec(À)).
We observed activation of innate immune cells such as monocytes and dendritic cells (DCs) by tumor vaccine infected with the rec(GM-CSF) when compared to vaccine infected with rec(À). We will show that rec(GM-CSF) vaccine leads to an enhanced IFN-a production by PBMC, which is due to the activity of monocytes and plasmacytoid DCs (PDCs).
In conclusion, our results provide the proof of principle that an incorporated therapeutic gene further augments the immunostimulatory and anti-neoplastic properties of NDV. This opens new possibilities for further optimization of the ATV-NDV tumor vaccine 13, 14, 16 and for systemic application of recombinant NDV with incorporated therapeutic genes.
Results

Production of recombinant NDV viruses with the GM-CSF gene
Two new recombinant (rec) NDV strains each containing the human GM-CSF gene incorporated at different positions within the viral genome (in front of the NP gene and between the HN and L gene, see Figure 1a ) were generated by reverse genetics. We also generated a rec virus with a murine GM-CSF gene in front of the NP gene. The genes were cloned into the plasmid pNDFL+, 15 which contains the viral genome of NDV. A DNA fragment containing the gene encoding human or murine GM-CSF was obtained by means of PCR using the plasmid pCD-hGM-CSF as template. It was then inserted into plasmid pNDFL+ between the transcriptionstart box of the NP gene and the NP open reading frame. 15 In order to allow transcription of downstream genes, a synthetic nucleotide sequence corresponding to the consensus transcription-end box and transcriptionstart box (ATTAAGAAAAAATACGGGTAGAAG) of NDV was inserted behind the therapeutic gene. The resulting plasmid was used to rescue recombinant NDV as described previously. 15 The rescued virus was designated rec(GM-CSF) or rec(mGM-CSF) respectively. The hGM-CSF gene was also inserted between the HN and L gene of NDV by replacing the SEAP gene in plasmid pHZ-SEAP/HN-L 17 and by rescuing the virus referred here as rec(GM-CSF (II)). All rec NDV strains could be grown to high titers in the allantoic fluid of embryonated chicken eggs.
Production of GM-CSF and biological activity
As shown in Figure 1b , human MCF-7 breast carcinoma cells infected with rec(GM-CSF) produced five times more gene product in comparison to rec(GM-CSF (II)). No GM-CSF protein could be detected in the supernatant of tumor cells infected with rec(À) virus (data not shown). Thus, the integration site of the therapeutic gene within the viral genome has a strong influence on the level of the protein expressed. The supernatants had the capacity to stimulate the growth of the GM-CSFdependent cell line TF-1 in a linear dose-dependent manner (Figure 2a) .
To test for biological activity, we added supernatants from murine ESb tumor cells infected by rec(mGM-CSF) or rec(À) virus to murine bone marrow derived cells and evaluated the generation of CD11c-positive DCs after 10 days of cultivation. As shown in Figure 2b , the supernatant from rec(mGM-CSF)-infected tumor cells caused a similar expansion of bone marrow cell numbers and maturation of DCs as the positive control, a supernatant from Ag8653 tumor cells producing mGM-CSF.
We conclude that the production of rec NDV viruses with incorporated human or murine genes is feasible and that the viruses produce a gene product with biological activity.
Main characteristics of rec(GM-CSF) virus
For tumor vaccine production it is important to know tumor cell-binding properties, virus replication behavior 
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M Janke et al and cytotoxic effects. Therefore, we investigated these aspects for the strains rec(À) and rec(GM-CSF) and compared them with NDV strain Ulster. As target cells we used the human breast carcinoma line MCF-7 (Figures 3a and b) , the human breast hyperplasiaderived epithelial cell line MCF-10A, the colon-carcinoma line HT29 and the T-cell lymphoma line Jurkat. The rec virus strains derived from lentogenic NDV La Sota behaved in all cell lines similar to the lentogenic NDV Ulster. Viral replication in the cytoplasm was associated with an increase of the density of cell surface-expressed viral HN and F proteins. The rec strains were also similar to NDV Ulster in that they were not able to replicate in normal human cells and that supernatants from infected tumor cells were non-infectious due to an uncleaved Fprotein in the newly synthesized virion particles (data not shown).
We also compared the rec strains and wild-type NDV Ulster with regard to their capacity to induce late apoptotic events in MCF-7 breast carcinoma cells (Figure 3c ). The recombinant viruses were about three times more effective in inducing cytotoxicity in the tumor cells than NDV Ulster. Only a small difference was seen between rec(À) and rec(GM-CSF) viruses.
Expression and stability of the therapeutic gene product
We infected the above four cell lines and tested their supernatants by enzyme-linked immunosorbent assay (ELISA) for content of GM-CSF after 48 h of in vitro culture. Rec(GM-CSF) expressed its gene product in all four tumor cell lines tested. The highest expression was found in MCF-7 cells (Figure 4 ; 128 ng GM-CSF ml À1 ). These were followed by MCF-10A and Jurkat cells, while the lowest expression was seen in HT29 cells, which produced only 34 ng GM-CSF ml
À1
. We then studied the kinetics of cytokine production and also the effect of g-irradiation of the infected cells on their capacity to produce cytokine. Figure 4a shows that g-irradiation had only a small effect on GM-CSF production. Maximum levels of cytokine expression were seen after 48 h of cell culture.
We then evaluated the expression of the therapeutic gene product in dependence on the number of irradiated MCF-7 vaccine cells added per well of a 96-well plate. While 750 cells produced only 12 ng ml À1 cytokine, 96 000 cells produced 390 ng ml À1 GM-CSF (Figure 4b ). Of further importance was the question of stability. Supernatants taken 1, 2, 3 or 4 days after infection were centrifuged and stored at À20 1C, 4 1C or incubated at 37 1C for 30 days before analyzing the specific protein content by ELISA. The results (Table 1) show that GM-CSF was stable for 30 days at body temperature.
Effect of GM-CSF-producing tumor vaccine in a tumor neutralization assay
This functional assay is basically a mixed lymphocytetumor vaccine culture (MLTC) run on top of a tumor cell monolayer. It enables to test human PBMC-mediated bystander antitumor, cytotoxic or cytostatic effects on the tumor monolayer. While we previously performed the tumor neutralization assay (TNA) in 96-well plates with 750 vaccine cells, 18 we had to increase the vaccine cell number to have enough of the therapeutic gene product ; top), of supernatant from Ag8653 cells that produce mouse GM-CSF (positive control, middle) or of supernatants from ESb-LCI cells infected with rec(mGM-CSF) for 72 h (5 Â 10 5 cells ml À1 ; bottom) was added. The fourth group corresponding flow cytometry to X-Vivo20 medium without any supplement showed the same FACS profile as the first flow cytometry group (top). The medium was changed every 3 days. On day 10, the cells were labeled with FITClabeled anti-mouse CD11c antibody and PE-labeled anti-H2D d antibody (both diluted 1:100) before being analyzed by flow cytometry. FITC, fluorescein isothiocyanate; GM-CSF, granulocyte/macrophage colony-stimulating factor NDV as vector for therapeutic genes in tumor therapy M Janke et al produced during the assay. An optimized test was thus established in 48-well plates containing 24 000 vaccine cells (V) and 96 000 PBMC as responder cells.
After 5-6 days of culture, the amount of live tumor cells was measured by uptake of the vital dye 3-(4, 5-dimethylthiazol-2-yl)-5-(3 carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) and the produced brown color was quantified in an ELISA reader at 490 nm.
These assays were performed with PBMC from 14 different healthy donors because of individual variability in activity. While in absence of virus infection the vaccine cells (V) did not induce tumor growth inhibition (TGI) (see Figure 5 ), we observed about 30% TGI when virusmodified vaccine cells (VN) were added on top of the tumor cell monolayer. Upon addition of PBMC we saw a further increase of TGI up to 80%, while PBMC without vaccine cells had no growth inhibitory effect. The results are summarized in Figure 5 . The highest mean of 82.3% TGI was obtained with rec(GM-CSF) in presence of PBMC. This was significantly higher than the effect seen with rec(À) and PBMC and thus provides the proof of principle of an added value of the incorporated gene for the tumor vaccine. NDV as vector for therapeutic genes in tumor therapy M Janke et al
Effect of the recombinant viruses on the IFN-a response of PBMC
To elucidate mechanisms, which could explain the observed higher antitumor activity when using rec(GM-CSF) instead of rec(À)-infected tumor vaccine, we analyzed the supernatants of the TNA for the expression of a panel of cytokines. These tests revealed that the amount of IFN-a was significantly higher in the TNA assays performed with rec(GM-CSF) than those with rec(À). When the TNA was performed with human purified T cells instead of PBMC as effector cells, no increase of IFN-a was seen (data not shown).
We next tested the IFN-a response of PBMC after coincubation with increasing amounts of either rec(À) or rec(GM-CSF). The results obtained with PBMC from 10 different healthy donors are shown in Figure 6a . rec(GM-CSF) induced a significantly higher IFN-a response in comparison to rec(À). Also, rec(GM-CSF)-infected MCF-7 vaccine cells induced an IFN-a response in PBMC, which was significantly higher than that induced by rec(À)-infected vaccine cells (Figure 6b ). PBMC control cultures or those stimulated with uninfected vaccine cells (data not shown) were negative. True infection of tumor cells by the rec viruses was important since UV inactivated virus was much less efficient (data not shown).
The increased IFN-a response of PBMC to rec(GM-CSF) virus could theoretically be due to a combined effect of GM-CSF and infection by NDV. The results from experiments testing this possibility are shown in Figure  6c . When recombinant GM-CSF protein (recGM-CSF) was added to rec(À) virus or V(rec(À)) vaccine to stimulate PBMC, we did not observe an increased IFNa response. Even higher amounts of GM-CSF did not work while rec(GM-CSF) virus was effective over a broad dose range (data not shown). Thus, rec(GM-CSF) is a new vector with an added value in comparison to rec(À) virus and also in comparison to GM-CSF protein.
To find out which cell types in PBMC are responsible for the increased IFN-a response seen with rec(GM-CSF), we tested purified monocytes, which were positively GM-CSF, granulocyte/macrophage colony-stimulating factor; ELI-SA, enzyme-linked immunosorbent assay. MCF-7 cells were infected with rec(GM-CSF) (100 HU per 10 7 cells per ml) and cultured as described for Figure 1b . After culture for 24, 48, 72 and 96 h, the supernatants were collected and stored at three different temperatures (À20, 4 and 37 1C) for 30 days. All samples were simultaneously analyzed for GM-CSF by ELISA. Numbers in brackets represent the percentage of GM-CSF concentration determined after storage at 4 or 37 1C taking as reference the sample stored at À20 1C. 
Discussion
The aim of the study was to further improve the tumor vaccine ATV-NDV, which is elaborated by infection of irradiated tumor cells with the lentogenic strain Ulster of NDV and showed promising results in clinical studies. 13, 14, 16 To this end, we inserted an additional gene coding for GM-CSF within the viral genome in such a way that viral infection of tumor cells leads to secretion of GM-CSF. We show here that the insertion of this additional therapeutic gene significantly increases the immune stimulatory properties of the virus and the antitumor effects of a respective tumor vaccine in a tumor neutralization assay in vitro. Using NDV as vector for tumor gene therapy offers several advantages over other viral expression systems: (1) high safety profile. This is due to the fact that NDV is an avian RNA virus. Viral infection and replication occur exclusively in the cytoplasm. No viral DNA is generated and no genetic recombination can occur with host cell DNA; (2) tumor cell infection efficiency. All the tumor cell lines tested in our laboratory were easy to infect and showed a high permissivity with 80% of the cells being infected. Viral replication is independent of cell proliferation and proceeds efficiently in tumor cells inactivated by g-irradiation. 20 Already after 24 h, the cells are fully infected by the virus. No selection for tumor cell transfectants is necessary as is the case with retroviral vectors for which technical hurdles have been described. 21 In fact the efficiency of the retroviral vector approach was so low that from 116 malignant gliomas only three transfectants were successfully established and could be applied to the patients. 21 For comparison, in our glioblastoma study, 13 the efficiency of ATV-NDV tumor vaccine production (autologous cell cultures plus virus infection) was 90%.
Since NDV is a negative strand RNA virus, reverse genetics technology had to be employed for the elaboration of recombinant NDV. The rescue system has been established with the strain La Sota. 15 Cloned La Sota virus NDFL was found to have similar properties as Ulster. The La Sota strain has already been shown to be safe in a clinical trial with stage I-IV malignant tumors of the digestive tract. 22 Other data obtained by us (not shown here) revealed that NDFL (i) shows tumor selective replication as observed for NDV Ulster, 23 (ii) has a monocyclic replication cycle in tumor cells and (iii) produces noninfectious progeny virus similar to NDV Ulster. 21 The only difference between the two virus strains was that NDFL (rec(À)) had about three times higher cytotoxic effects on tumor cells as revealed by the Nicoletti assay. Such increased tumor cytotoxic effect may lead to an improvement of the immune response through uptake of apoptotic bodies and cross-presentation of tumor-associated antigens via host DCs. 24 Secretion of GM-CSF by infected tumor cells should activate 7 PBMC or to MCF-7 vaccine cells pre-infected with rec(À) as in (b) in a final volume of 500 ml. After 24 h, the supernatants were tested for IFN-a by ELISA. NS, not significant. IFN-a, interferon-a; GM-CSF, granulocyte/macrophage colony-stimulating factor; PBMC, peripheral blood mononuclear cells.
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M Janke et al and attract antigen-presenting cells, thereby inducing a tumor-specific cellular immune response. The GM-CSF of the vaccine produced with rec(GM-CSF) could further stimulate this process by recruiting more DCs to the site of vaccination and by improving cross-presentation via IFN-a and by upregulation of costimulatory molecules on DCs. This is a critical first step in the induction of an optimal immune response to any immunotherapy product at the injection site. 25, 26 GM-CSF appears to be a very attractive therapeutic gene because it was the most potent among multiple cytokines and growth factors transduced into a syngeneic, non-immunogenic, B16 melanoma tumor cell vaccine. 26, 27 GM-CSF was shown to recruit and maturate DCs, macrophages and neutrophils. 26 It showed already interesting effects in vaccination studies 25, [27] [28] [29] and also some objective clinical regression of metastatic breast cancer. 30 In this study, two positions of insertion for the GM-CSF therapeutic gene were tested. The position close to the 3 0 proximal end showed a higher recombinant protein expression than the other one. The NDV RNAdependent RNA polymerase initiates its binding to the RNA template at the leader sequence close to the 3 0 end of the genomic RNA. It performs the transcription of the six different genes within the viral genome in a discontinuous manner by starting the transcription of each gene at the Gene Start (GS) sequence and ending it at the Gene End (GE) sequence. This leads to the generation of a gradient of mRNAs from the 3 0 end to Figure 7 IFN-a response to rec(GM-CSF) virus by monocytes and plasmacytoid DCs. Monocytes were purified or depleted from PBMC of a healthy donor using anti-CD14-specific mAb and magnetic beads. Staining and flow cytometry analysis confirmed a high purity of the obtained monocytes fraction. A 5 HU of rec(À) or rec(GM-CSF) (or no virus as control) was added to 5 Â 10 5 cells in 24-well plates (500 ml volume per well) to the monocytes (a) or to the remaining CD14 depleted PBMC (b). c and d additionally contained anti-BDCA-2 mAb or isotype control mAb, respectively (3 mg ml
À1
). After 1 day of incubation, the level of IFN-a was determined by ELISA. IFN-a, interferon-a; GM-CSF, granulocyte/macrophage colony-stimulating factor; PBMC, peripheral blood mononuclear cell; ELISA, enzyme-linked immunosorbent assay; mAb, monoclonal antibody.
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0 end and a corresponding gradient in the amounts of the different proteins. This explains the faster (within the first 24 h) and stronger expression of the therapeutic gene product when testing the virus with the GM-CSF gene inserted in front of the NP gene. Furthermore, irradiation of the tumor cells before infection with rec(GM-CSF) did not interfere with the level of protein produced.
GM-CSF expressed by rec(GM-CSF)-infected tumor cells was stable up to 30 days and it was biologically active. The cytokine served as a growth factor for GM-CSF-dependent TF-1 cells and murine bone marrow cells and caused maturation of DCs. GM-CSF was not only produced by tumor cells but also by PBMC upon infection with rec(GM-CSF) (data not shown). We reported before that NDV can infect PBMC and produce positive strand viral RNA 23 but the antiviral response of PBMC 23 prevents further viral replication and associated cell death.
To investigate the antitumoral activity of PBMC upon stimulation with tumor vaccine cells infected by rec viruses, we used a previously established TNA, which allows testing for bystander antitumor activity. We demonstrate that bystander antitumor activity can be increased significantly when using rec(GM-CSF) virus in comparison to rec(À) virus for the elaboration of the tumor vaccine. These TNA experiments were performed with 14 different PBMC donors because of the great variability in the activity of PBMC from different donors. The findings corroborate results from other tumor vaccine systems in which either vaccinia virus, 31 retrovirus 30 or HSV-1 amplicons 32 were used as vectors to transfer the GM-CSF gene into tumor cells.
An unexpected but encouraging finding was that PBMC responded to addition of rec(GM-CSF) with a strong production of IFN-a. This response was significantly higher than the IFN-a response to either rec (À) virus or to recombinant GM-CSF. There seems to be a synergistic effect in this response between virus infection and production of GM-CSF thus providing rec(GM-CSF) with an added value in comparison to the recombinant protein. Addition of irradiated MCF-7 vaccine cells infected with rec (GM-CSF) to PBMC also showed a significantly enhanced IFN-a response. IFN-a has a central importance not only as an antiviral agent but also for innate and adaptive immune responses. 19, 33 It may thus also be involved in the observed increased bystander antitumor effects.
Recent preclinical studies have demonstrated further enhancement of antitumor immunity when a tumor vaccine secreting GM-CSF is combined with (i) blockade of CTLA-4, 34 (ii) blockade of vascular endothelial growth factor 35 or (iii) immunomodulatory doses and schedules of certain chemotherapeutic agents. 36 Also a combination of IFN-a and GM-CSF secreting tumor vaccine was shown to significantly enhance the potency of the immunotherapeutic effect. 37 The expression of the HN protein of NDV at the cell surface of the ATV-NDV tumor vaccine 5 as well as the replication of NDV within these cells may be of central importance for the induction of IFN-a at the vaccination site and consequently for the observed antitumor response in clinical studies based on NDV tumor vaccine. 16 Here, we show that a tumor vaccine obtained by irradiation and infection with rec(GM-CSF) induces a stronger IFN-a response in human monocytes and PDCs than a vaccine infected with the virus without incorporated foreign gene. Interestingly, rec(GM-CSF) virus was found to exert immunostimulatory effects; which were superior to a mixture of rec(À) virus and GM-CSF protein. Earlier experiments had revealed that the type I IFN response leads to upregulation of TRAIL on monocytes and to monocyte mediated antitumor cytotoxicity. 38 Soluble TRAIL-Fc molecules were able to inhibit such cytotoxicity 38 and they also inhibited partially (about 50%) the effects measured by the TNA test (data not shown). Preliminary tests also revealed that in a TNA with rec(GM-CSF)-infected vaccine, monocytes show increased TRAIL expression, DCs show increased expression of CD80 and CD86 costimulatory molecules and tumor cells from the monolayer show increased expression of Apo 2.7, a marker for early apoptotic events (M Janke, unpublished results). Through the stronger activation of innate immune effects, we expect that a tumor vaccine infected with rec(GM-CSF) will also induce a stronger adaptive immune response because IFN-a provides a link between both immunity systems. 39, 40 In summary, this study shows that the immune stimulatory and antitumoral properties of NDV can be further augmented by incorporation of a foreign gene. More specifically our data suggest that rec(GM-CSF), a recombinant NDV that produces GM-CSF and induces a strong IFN-a response represents a promising new viral vector for human tumor immunogene therapy.
Materials and methods
Antibodies and chemicals
For flow cytometry analysis, the following mAbs against mouse antigens were used at 1:100 dilution: CD11c-FITC, For blocking experiments, we used unlabeled antihuman BDCA-2 (IgG1) mAb at 3 mg ml À1 (Miltenyi, Bergisch Gladbach, Germany). The isotype control HD20 (IgG1) was a gift from Dr Gerd Moldenauer (DKFZ, Heidelberg, Germany) and was used at identical concentrations. ELISA experiments for the detection of human GM-CSF (Pharmingen, Hamburg, Germany) and human IFN-a (Bender Medsystems, San Bruno, CA, USA) were performed in accordance to the manufacturer's guidelines. Recombinant GM-CSF protein (commercial trade name: Leukine Sargramostin) was purchased from Berlex Laboratories Inc. (Richmond, VA, USA).
MTS Cell Titer 96 Aqueous solution was purchased from Promega (Mannheim, Germany).
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Cell lines and culture
All tumor cells were obtained from the Tumorbank DKFZ (Heidelberg, Germany) except the MCF-10A human breast hyperplasia-derived cell line, which was purchased from ATCC (Manassas, VA, USA). The human Jurkat cell line was grown in RPMI-1640 medium supplemented with 10% inactivated fetal calf serum (FCS), 2 mM L-glutamine, 10 mM HEPES, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. The human breast carcinoma cell line MCF-7 and the human colon-adenocarcinoma cell line HT29 were maintained in Dulbecco's modified Eagle's medium containing 10% inactivated FCS, 2 mM L-glutamine, 10 mM HEPES, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. The non-tumorigenic but immortalized human breast epithelial cell line MCF-10A was cultured in Dulbecco's modified Eagle's medium with 5% horse serum, 10 mM HEPES, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin, 500 ng ml À1 hydrocortisone, 0.01 mg ml À1 insulin, 20 ng ml À1 epidermal growth factor and 100 ng ml
À1
choleratoxin. TF-1 is a human premyeloid cell line, which was originally established by Dr Kitamura from a patient with erythroleukemia. This cell line, whose growth is dependent on GM-CSF was purchased from ATCC (cat. no. CRL-2003). The myeloma cell line Ag8653 expressing mouse recombinant GM-CSF was cultured to produce mouse GM-CSF. All these cells were grown in RPMI-1640 medium with 10% FCS, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin, 10 mM HEPES, 1mM sodium pyruvate, 2.5 mg ml À1 glucose and 25 mg ml À1 GM-CSF. All reagents for cell culture were purchased from Gibco Life Technologies (Karlsruhe, Germany) except FCS, which was from Biochrom (Krefeld, Germany) and the horse serum, hydrocortisone, insulin, epidermal growth factor and choleratoxin were purchased from Sigma (Deisenhofen, Germany). GM-CSF used as standard was obtained from Promocell (Heidelberg, Germany). All cell lines were incubated at 37 1C in a humidified atmosphere of 5% CO 2 .
Plasmids and virus
The plasmid called pNDFL, which contains the six genes of the negative-stranded RNA genome of NDV strain La Sota in the order 3 0 -NP-P-M-F-HN-L-5 0 has been described by Peeters et al. 15 The plasmid pCD-hGM-CSF encoding the human GM-CSF gene was purchased from ATCC (cat. no. 57594).
NDV-Ulster 2C was obtained in 1984 from Dr PH Russel (University London, UK).
All the viruses (recombinant or not) were propagated in embryonated chicken eggs, harvested from the allantoic fluid, purified by ultracentrifugation and quantified by hemagglutination as described previously. 2 In some experiments, the virus was inactivated with UV light for 5 min (254 nm, 2 mW cm À2 , 7 cm distance).
Purification of blood-derived cells
Human PBMCs were isolated from buffy coat of healthy donors by Ficoll-Paque (Amersham Pharmacia Biotech, Freiburg, Germany) density gradient centrifugation.
In some assays, PBMCs were depleted from monocytes by using magnetic beads coated with CD14-specific mAbs and MACS columns (both Miltenyi, Bergisch Gladbach, Germany). We also tested the positively selected CD14 + monocytes.
Production of virus-infected tumor vaccine stimulator cells
As stimulator cells for mixed lymphocyte-tumor cell cultures (MLTC) and the TNA, we used MCF-7 breast carcinoma cells that were inactivated with 200 Gy irradiation via a 137 Cs source (Gammacell 1000, Atomic Energy of Canada, Chalk River, Canada) and then infected with the respective NDV strain (100 HU per 10 7 cells per ml) as described. 2 
Flow cytometry
A total of 5 Â 10 5 cells were used per sample. All antibodies were diluted in flow cytometry buffer (PBS containing 5% FCS and 0.1% NaN 3 ) as described in the antibody section. Cells were incubated with a primary (un-) conjugated antibody for 20 min on ice in the dark. Subsequently cells were washed two times with flow cytometry buffer and, if necessary incubated with a conjugated secondary antibody for 20 min on ice in the dark. Then the cells were washed two times, adjusted to a volume of 100 ml and analyzed in a FACS Calibur flow cytometer (Becton & Dickinson, Heidelberg, Germany). All flow cytometry data were analyzed with CELLQuest Pro software (Becton & Dickinson, Heidelberg, Germany).
Apoptosis assays
For determination of late apoptotic cells a Nicoletti staining was performed. Briefly, 5 Â 10 5 cells were washed in PBS, incubated with 250 ml Nicoletti solution (0.05 mg ml À1 propidium iodide, 0.1% sodium citrate and 0.1% Triton X-100 in PBS) for at least 48 h at 4 1C in the dark and then analyzed by flow cytometry.
Tumor neutralization assay
The assay was performed in 48-well round-bottom plates. A total of 1.4 Â 10 4 live MCF-7 tumor cells in Dulbecco's modified Eagle's medium with 5% FCS were added to each well and incubated for 4 h at 37 1C to adhere.
Subsequently, 9.6 Â 10 4 freshly isolated non-activated PBMC from normal healthy donors were added to the respective wells. A total of 2.4 Â 10 4 stimulator cells per well were prepared by irradiation and virus infection as indicated. The total volume per well was 400 ml. The microtiter plates were then wrapped in cling film to prevent evaporation of medium and incubated in a CO 2 incubator at 37 1C. The time of incubation depended on the time for confluence of the tumor cell monolayer in control wells without stimulator or effector cells. All experimental wells were performed in triplicates. At the end of the assay, supernatants were removed by suction and the plates were carefully washed twice with RPMI containing 5% FCS to remove effector and stimulator cells. Then 200 ml of RPMI with 5% FCS and 40 ml MTS solution (3-(4,5-dimethythiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS) were added per well and incubated for 20-40 min at 37 1C in the dark. After color switch, the reaction was stopped by transfer of each well content to a 96-well plate containing 20 ml 10% SDS per well. The plates were then evaluated One day prior to the assay, the indicator cells were transferred to cytokine-free medium. For the assay, the cells were then harvested, washed three times with cytokine free medium and adjusted to a cell number of 2 Â 10 5 ml
À1
. A 50 ml of cell suspension was added to a 96-well plate, which contained serial 1:4 dilutions of the supernatants of infected tumor cells. The assay was performed in duplicates for each dilution step. After 48-72 h at 37 1C 1 mCi
